medigraphic.com
ISSN 1025-0298 (Digital)
ISSN 1025-028X (Impreso)

2021, Número 2

<< Anterior

VacciMonitor 2021; 30 (2)


Empleo de la vacuna Euvax-B en la provincia de Nínive

Dawood AA, Altobje MA, Al-Rrassam ZT

Idioma: Ingles.
Referencias bibliográficas: 25
Paginas: 91-95
Archivo PDF: 345.53 Kb.


RESUMEN

La infección por hepatitis B es uno de los más importantes problemas de salud del mundo. La alta tasa de mortalidad de la hepatitis B impulsó las investigaciones que llevaron a encontrar una vacuna eficaz contra la misma. El objetivo del presente estudio fue conocer el uso de la vacuna Euvax-B en sectores de la provincia de Nínive. De acuerdo con los resultados obtenidos, en los próximos cinco años, se debe incrementar la cobertura de inmunización de la segunda y tercera dosis de la vacuna.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Wiesen E, Diorditsa S, Li X. Progress towards hepatitis B prevention through vaccination in the Western Pacific, 1990-2014. Vaccine. 2016;34:2855-62.doi:https://10.1016/j.vaccine.2016.03.060.

  2. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet.2015;386:1546-55. doi: https://10.1016/S0140-6736(15)61412-X.

  3. Han S. Clinical vaccine development. Clin Exp Vaccine Res 2015; 4:46-53. doi: https://10.7774/cevr.2015.4.1.46.

  4. Bian T, Yan H, Shen L, Wang F, Zhang S, Cao Y, et al. Change in hepatitis B virus large surface antigen variant prevalence 13 years after implementation of a universal vaccination program in China. J Virol. 2013;87:12196-206. doi:https://10.1128/JVI.02127-13.

  5. Lian ZL, Tian QN, Liu Y, Cento V, Salpini R, Perno CF, et al. Detecting Hepatitis B Viral Amino Acid Sequence Mutations in Occult Hepatitis B Infections via Bayesian Partition Model. J Proteomics Bioinform. 2013; S6-005. doi:https://10.4172/jpb.S6-005.

  6. Cha SH. The history of vaccination and current vaccination policies in Korea. Clin Exp Vaccine Res 2012;1:3-8.

  7. Lok AS, Pan CQ, Han SH, Trinh HN, Fessel WJ, Rodell T,et al. Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B. J Hepatol. 2016;65:509-16. doi:https://10.1016/j.jhep.2016.05.016.

  8. Yang S, Tian G, Cui Y, Ding C, Deng M, Yu C, et al. Factors influencing immunologic response to hepatitis B vaccine in adults. Sci Rep 2016;6:27251. doi: https:// 10.1038/srep27251.

  9. Lin AW, Wong KH. Long-term protection of neonatal hepatitis B vaccination in a 30-year cohort in Hong Kong. J Hepatol 2013;59:1363-4. doi:https://10.1016/j.jhep.2013.08.021.

  10. Sandhu P, Haque M, Humphries-Bickley T, Ravi S, Song J. Hepatitis B virus immunopathology, model systems, and current therapies. Front Immunol. 2017; 8:436. doi: https://10.3389/fimmu.2017.00436.

  11. Lee LY, Chan SM, Ong C, M Aw M, Wong F, Saw S, et al. Comparing monovalent and combination hepatitis B vaccine outcomes in children delivered by mothers with chronic hepatitis B. J Paediatr Child Health. 2019;55:327-32. doi: https://10.1111/jpc.14194.

  12. Schillie S, Vellozzi C, Reingold A, Harris A, Haber P, Ward JW, et al. Prevention of hepatitis B virus infection in the United States: Recommendations of the advisory committee on immunization practices. MMWR Recomm Rep. 2018; 67:1-31. doi: https://10.15585/mmwr.rr6701a1.

  13. Chen X, Tang Y, Zhang Y, Zhuo M, Tang Z, Yu Y, et al. Tapasin modification on the intracellular epitope HBcAg18-27 enhances HBV-specific CTL immune response and inhibits hepatitis B virus replication in vivo. Lab Invest. 2014;94:478-90. doi: https://10.1038/labinvest.2014.6.

  14. Chen TW. Paths toward hepatitis B immunization in South Korea and Taiwan. Clin Exp Vacc Res. 2013; 2:76-82. doi: https://10.7774/cevr.2013.2.2.76.

  15. World Health Organization. Hepatitis B vaccines: WHO position paper, July 2017 - Recommendations. Vaccine. 2019; 37:223-5. doi: https://10.1016/j.vaccine.2017.07.046.

  16. Shimakawa Y, Lemoine M, Njai HF, Bottomley C, Ndow G, Goldin RD, et al. Natural history of chronic HBV infection in West Africa: a longitudinal population based study from The Gambia. Gut. 2016; 65: 2007-16. doi: https://10.1136/gutjnl-2015-309892.

  17. Shouval D, Roggendorf H, Roggendorf M. Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S vaccine. Med Microbiol Immunol. 2015; 204:57-68. doi: https://10.1007/s00430-014-0374-x.

  18. Gong J, Liu X. Effect of HBIG combined with hepatitis B vaccine on blocking HBV transmission between mother and infant and its effect on immune cells. Exp Ther Med. 2018;15:919-23. doi: https://10.3892/etm.2017.5474.

  19. Sticchi L, Caligiuri P, Cacciani R, Alicino C, Bruzzone B. Epidemiology of HBV S-gene mutants in the Liguria Region, Italy: Implications for surveillance and detection of new escape variants. Hum Vaccin Immunother. 2013;9:568-71. doi: https://10.4161/hv.23236.

  20. Meireles LC, Marinho RT, Van Damme P. Three decades of hepatitis B control with vaccination. World J Hepatol. 2015;7:2127-32. doi: https://10.4254/wjh.v7.i18.2127.

  21. Dawood A, and Altobje M. Correlation between CXCL-motif-10 and IFN- ? on Hemodialysis Patients with HCV under Treatment. Int J Eme Tech. 2019; 10(3): 208-215.

  22. Leroux-Roels G. Old and new adjuvants for hepatitis B vaccines. Med Microbiol Immunol. 2015; 204:69-78. doi: https://10.1007/s00430-014-0375-9.

  23. Ninawa PHI. Yearly Report for Transport Diseases and Vaccination in Nineveh. 2018, Mosul: DPHS;2018.

  24. Dawood A, Hasan G, Hayawi A. Determination Genotype D of Hepatitis B Virus amongst Patients in Mosul-Iraq. Int J Sci & Tech Res. 2019; 8(9): 1218-1220.

  25. Tajiri K, Shimizu Y. Unsolved problems and future perspectives of hepatitis B virus vaccination. World J Gastroenterol. 2015; 21:7074-83. doi: https://10.3748/wjg.v21.i23.7074.




2020     |     www.medigraphic.com